ArriVent BioPharma, Ownership
| AVBP Stock | 19.52 0.02 0.10% |
ArriVent |
ArriVent Stock Ownership Analysis
About 85.0% of the company shares are held by institutions such as insurance companies. The book value of ArriVent BioPharma, was presently reported as 7.64. The company recorded a loss per share of 2.56. ArriVent BioPharma, had not issued any dividends in recent years. For more info on ArriVent BioPharma, Common please contact the company at 628 277 4836 or go to https://www.arrivent.com.ArriVent BioPharma, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ArriVent BioPharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on ArriVent BioPharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ArriVent BioPharma, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Orbimed Advisors Llc a day ago Discretionary transaction by Orbimed Advisors Llc of 821827 shares of ArriVent BioPharma, subject to Rule 16b-3 | ||
Hillhouse Investment Management, Ltd. over six months ago Acquisition by Hillhouse Investment Management, Ltd. of 555555 shares of ArriVent BioPharma, at 18.0 subject to Rule 16b-3 | ||
Hillhouse Investment Management Ltd over a year ago Conversion by Hillhouse Investment Management Ltd of 3616041 shares of ArriVent BioPharma, | ||
Gordon Carl L over a year ago Conversion by Gordon Carl L of 821827 shares of ArriVent BioPharma, | ||
Gordon Carl L over a year ago Conversion by Gordon Carl L of 469615 shares of ArriVent BioPharma | ||
Jallal Bahija over a year ago Acquisition by Jallal Bahija of 17884 shares of ArriVent BioPharma, subject to Rule 16b-3 | ||
Gordon Carl L over a year ago ArriVent BioPharma exotic insider transaction detected |
ArriVent BioPharma, Outstanding Bonds
ArriVent BioPharma, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ArriVent BioPharma, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ArriVent bonds can be classified according to their maturity, which is the date when ArriVent BioPharma, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| ARROW ELECTRS INC Corp BondUS042735BE98 | View | |
| ARROW ELECTRS INC Corp BondUS042735BF63 | View | |
| ARW 295 15 FEB 32 Corp BondUS04273WAC55 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| ARROW ELECTRS INC Corp BondUS042735AK67 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Pair Trading with ArriVent BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving against ArriVent Stock
The ability to find closely correlated positions to ArriVent BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma, Common to buy it.
The correlation of ArriVent BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.